查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1988242

Duchenne氏肌肉失養症治療市場：按藥物類別、劑型、給藥途徑、分銷管道和最終用戶分類－2026-2032年全球市場預測

Duchenne Muscular Dystrophy Drugs Market by Drug Class, Form, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Duchenne氏肌肉失養症治療市場價值將達到 18.5 億美元，到 2026 年將成長至 20.2 億美元，到 2032 年將達到 34.6 億美元，複合年成長率為 9.31%。

主要市場統計數據
基準年 2025 18.5億美元
預計年份：2026年 20.2億美元
預測年份 2032 34.6億美元
複合年成長率 (%) 9.31%

該計畫總結了整個生態系統中的科學進展、臨床重點和相關人員的需求，為Duchenne氏肌肉失養症。

Duchenne氏肌肉失養症仍然是臨床和商業性最複雜的罕見疾病領域之一，其特徵是進行性性肌肉退化，給看護者帶來沉重負擔，並且持續需要疾病修正治療。過去十年來的科學進步已將該領域的治療重點從對症治療轉向靶向分子干涉，從而構建了一個緊密的治療方法、監管合作和支付方參與策略的生態系統。臨床醫生、患者家屬和政策制定者越來越關注藥物的生物活性，同時也關注其帶來的顯著功能獲益、長期安全性以及永續的用藥模式。

醫療保健領域前所未有的科學、製造和價值導向的變革正在重塑Duchenne氏肌肉失養症治療的臨床開發、分銷和報銷策略。

近年來發生的變革性變化正在重新定義Duchenne氏肌肉失養症的治療研發和實施方式，影響臨床試驗設計、藥物生產和長期照護模式。科學創新使得針對該疾病潛在遺傳缺陷的標靶治療更加精準，從而從統一的治療方法的研發路徑。同時，測量科學也日趨成熟。新型功能性終點、數位生物標記和病患報告結局正被納入關鍵的研發項目中，以便在小規模、異質性更高的群體中也能獲得具有臨床意義的益處。

本研究評估了預計 2025 年美國關稅調整將如何影響Duchenne氏肌肉失養症治療的供應鏈、製造在地化選擇和市場進入策略。

貿易政策變化和關稅考量是生物製藥供應鏈策略規劃的關鍵要素，而美國提案於2025年進行的關稅調整將進一步增加Duchenne氏肌肉失養症治療領域企業的營運風險。生物製藥生產的原料，例如質體DNA、特殊試劑、一次性系統和腺相關病毒（AAV）生產原料，在其生產週期中往往需要多次跨境運輸。因此，關稅和海關重新分類可能導致總成本增加和前置作業時間延長，可能促使企業重新評估供應商的所在地。

透過將藥物類別、分銷管道、最終用戶背景、劑型和給藥途徑整合到以細分主導的策略中，可以獲得可操作的商業性和臨床見解。

從多個臨床和商業性觀點審視治療方法時，細分市場分析揭示了清晰的策略意義。藥物類別、外顯子跳躍劑、基因療法和類固醇療法都需要獨特的臨床開發模式和證據支持。在基因治療領域，基於腺相關病毒（AAV）和非病毒載體的治療方式之間的差異會影響載體選擇、免疫抗原性管理和生產路線決策。進一步考慮AAV血清型選擇，例如血清型6和血清型9，會影響組織標靶化、給藥策略和生產規模的複雜性。對分銷管道的檢驗突顯了醫院藥房、線上藥房和零售藥房之間不同的物流和合規要求。每個管道在低溫運輸管理、報銷和患者支援需求方面都面臨著不同的挑戰。從最終用戶的觀點來看，醫療保健環境中的要求與醫院和專科診所的要求有顯著差異，這會影響培訓、監測頻率以及對輸液相關事件的緊急應變準備。劑型和給藥途徑對藥物誘導和患者依從性至關重要。膠囊和口服藥片與注射和靜脈注射相比，能為患者帶來不同的體驗，而且每種給藥途徑——肌肉注射、靜脈注射和口服——都有其獨特的臨床監測和給藥基礎設施需求。

評估美洲、歐洲、中東和非洲以及亞太地區在監管、還款和營運方面的區域差異，並協助制定分階段的市場進入和存取策略。

區域趨勢影響Duchenne氏肌肉失養症治療的部署和准入路徑，每個地區都有其獨特的法規、報銷和營運考慮。在美洲，成熟的專科中心網路、完善的罕見疾病臨床試驗基礎設施以及優先考慮醫療技術評估和基於價值的合約的支付方，共同影響著藥物的核准順序和商業性上市。在歐洲、中東和非洲，監管路徑各不相同，報銷決策通常受國家監管機構的影響。由於監管機構對療效比較證據的要求各不相同，因此必須儘早協調不同的證據策略並建立區域特定的衛生經濟學模型。在亞太地區，臨床研究能力正在快速發展，與產業界合作的意願日益增強，生產生態系統也不斷多元化。然而，打入市場策略必須考慮到不同的監管要求、價格控制和患者准入計劃。

本研究分析了企業在載體工程、生產規模化和相關人員合作方面的策略如何決定Duchenne氏肌肉失養症治療的臨床開發和商業化準備進展。

公司層面的發展趨勢對Duchenne氏肌肉失養症治療領域的創新步伐和方向至關重要。專注於外顯子跳躍和小分子療法的生物技術公司不斷改進有效載荷的化學表徵、遞送方法和患者選擇標準，以增強臨床差異化。致力於基因替代療法的機構則專注於載體工程、血清型選擇和可擴展的GMP生產，以減少批次間差異並確保臨床供應的穩定性。在整個產業中，策略聯盟，例如研究合作、授權協議和生產夥伴關係，被廣泛用於彌補能力差距並縮短臨床試驗週期。

透過採用結合早期生產規劃、適應性證據產生、供應多樣化和以患者為中心的服務的綜合方法，我們降低了開發風險並加快了獲取途徑。

行業領導者應採取協調一致、風險平衡的方法，將科學策略與生產和市場進入計劃相結合，以加速對患者的持久影響。首先，將生產的考量納入早期臨床試驗設計決策，可降低後期供應受限的可能性，並有助於與監管機構就可比性和長期追蹤進行更清晰的討論。其次，企業應優先創建適應性證據，將可靠的臨床終點與可操作的真實世界資料收集結合。這有助於支援產品的迭代改進，同時滿足監管機構和支付方的需求。第三，供應商網路多元化和區域製造地建設可降低關稅和跨境風險，而與經驗豐富的生物製藥生產商簽訂長期產能合約則可確保關鍵原料的供應。

請描述一種混合方法分析方法，該方法結合了專家訪談、監管審查和供應鏈映射，以檢驗策略見解，而無需依賴數值化的市場規模估計。

本執行報告的基礎研究採用混合方法，旨在全面了解Duchenne氏肌肉失養症治療藥物研發的科學、運作和商業性層面。主要研究包括對臨床專家、生產專家、支付方顧問和患者權益組織代表進行結構化訪談，以檢驗治療方法的具體挑戰和證據預期。次要研究整合了同行評審文獻、監管指導文件、臨床試驗註冊資訊以及公司公開提交的文件，以梳理技術進展、安全性考慮和不斷變化的試驗終點。交叉檢驗階段將訪談結果與已記錄的證據進行比較，以確保一致性並減少偏差。

這整合了策略重點和營運要求，以決定Duchenne氏肌肉失養症治療方面的科學進步是否會帶來持續的臨床益處和更廣泛的患者群體。

總之，Duchenne氏肌肉失養症的治療格局正處於一個關鍵的轉折點，科學創新、生產現實和支付方的期望在此交匯，決定著哪些治療方法能夠惠及患者以及如何在臨床實踐中應用。外顯子跳躍、基因治療載體和最佳化類固醇療法的進展具有改變疾病進程的真正潛力，但要實現這一潛力，需要研發、生產和商業化團隊的協調規劃。對可擴展生產設施的策略性投資、與監管機構和支付方的早期溝通、全面的真實世界數據（REW）計劃以及健全的患者支持模式，將在將臨床潛力轉化為永續的患者可及性方面發揮至關重要的作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：Duchenne氏肌肉失養症治療市場：依藥物類別分類

  • 埃克森美孚跳過
  • 基因治療
    • 基於腺結合病毒（AAV）
      • 血清型 6
      • 血清型 9
    • 非病毒
  • 類固醇療法

第9章：Duchenne氏肌肉失養症治療市場：依形式分類

  • 膠囊
  • 注射藥物
  • 口服錠劑

第10章：Duchenne氏肌肉失養症治療市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服

第11章Duchenne氏肌肉失養症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章Duchenne氏肌肉失養症治療市場：依最終用戶分類

  • 家庭醫療保健設施
  • 醫院
  • 專科診所

第13章Duchenne氏肌肉失養症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章Duchenne氏肌肉失養症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章Duchenne氏肌肉失養症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國Duchenne氏肌肉失養症治療藥物市場

第17章：中國Duchenne氏肌肉失養症治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anuh Pharma Limited
  • Arlak Biotech Pvt.Ltd.
  • Aurigene Pharmaceutical Services Ltd.
  • Bayer Pharmaceutical
  • Cipla Inc.
  • Enomark
  • Glasier Wellness, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Lifecare Neuro Products Limited
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.,
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • QndQ Derma
  • RayBiotech, Inc.
  • Ronyd Healthcare Pvt Ltd.
  • Sarepta Therapeutics, Inc.
  • Sumitomo Corporation
  • Texas Pharmaceuticals Pvt. Ltd.
  • Wellona Pharma
  • Zuventus Healthcare Ltd.
Product Code: MRR-5E3B35529469

The Duchenne Muscular Dystrophy Drugs Market was valued at USD 1.85 billion in 2025 and is projected to grow to USD 2.02 billion in 2026, with a CAGR of 9.31%, reaching USD 3.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.85 billion
Estimated Year [2026] USD 2.02 billion
Forecast Year [2032] USD 3.46 billion
CAGR (%) 9.31%

Setting the stage for Duchenne muscular dystrophy therapeutic strategies by summarizing scientific progress, clinical priorities, and stakeholder imperatives across the ecosystem

Duchenne muscular dystrophy remains one of the most clinically and commercially complex rare disease areas, characterized by progressive muscle degeneration, substantial caregiver burden, and a persistent need for disease-modifying therapies. Scientific advances over the past decade have shifted the field beyond symptomatic care toward targeted molecular interventions, creating a dense ecosystem of therapeutic modalities, regulatory interactions, and payer engagement strategies. Clinicians, families, and policymakers increasingly demand evidence not only of biological activity, but of meaningful functional benefit, long-term safety, and sustainable access models.

Against this backdrop, industry participants face a landscape that requires integrated thinking across discovery, clinical development, manufacturing, and commercialization. Emerging modalities such as exon skipping, gene replacement strategies using AAV vectors, and refined corticosteroid regimens each carry distinct scientific rationales, regulatory considerations, and operational footprints. Moreover, as precision medicine techniques refine patient selection and outcome measurement, stakeholders must balance innovation with scalable manufacturing and distribution approaches. This executive summary synthesizes those dimensions, providing context for strategic decisions and highlighting levers that can accelerate translation from pipeline to patient impact.

Unprecedented scientific, manufacturing, and value-based care shifts are reshaping clinical development, distribution, and reimbursement strategies for Duchenne therapeutics

The past several years have produced transformative shifts that are redefining how Duchenne therapies are developed and delivered, with consequences for trial design, manufacturing, and long-term care models. Scientific innovations have enabled more precise targeting of the genetic defects underpinning the disease, prompting a move away from one-size-fits-all approaches toward modality-specific development paths that require bespoke regulatory and manufacturing strategies. Concurrently, measurement science has matured: novel functional endpoints, digital biomarkers, and patient-reported outcomes are being integrated into pivotal development programs to capture clinically meaningful benefit in smaller, more heterogeneous populations.

Operationally, the industry is experiencing a parallel transition. Gene-based therapeutics reliant on AAV vectors are driving urgent investments in vector manufacturing capacity, quality control, and long-term safety monitoring systems. The choice of serotype, such as AAV6 or AAV9, now influences distribution kinetics, tissue tropism, and manufacturing complexity, which in turn affects clinical strategy and commercial viability. At the same time, exon skipping agents and optimized corticosteroid approaches continue to be refined, offering differentiated profiles in terms of administration, monitoring, and patient populations. These technological and procedural shifts are fostering new partnerships between biotech innovators, contract manufacturers, and specialty pharmacies, while also prompting payers and health systems to explore outcomes-based reimbursement and risk-sharing models to manage high upfront costs with uncertain long-term benefit trajectories.

Taken together, these shifts demand that industry leaders integrate scientific, manufacturing, and commercial planning earlier in development to de-risk late-stage programs and align stakeholder expectations around real-world evidence collection and patient access.

Assessing how anticipated United States tariff adjustments in 2025 may influence supply chains, manufacturing localization choices, and commercial access strategies for Duchenne therapies

Trade policy changes and tariff considerations have become material factors in strategic planning for biopharma supply chains, and proposed tariff adjustments in the United States during 2025 represent an additional variable for companies operating in the Duchenne therapeutic space. Raw materials for biologics production, including plasmid DNA, specialized reagents, single-use systems, and AAV manufacturing inputs, often cross borders multiple times during the manufacturing lifecycle. Consequently, tariffs or customs reclassifications can increase landed costs, extend lead times, and create incentives to re-evaluate supplier footprints.

In response, organizations are reassessing near-term sourcing strategies and exploring diversification to mitigate exposure. Some are accelerating investments in localized production capacity or entering long-term supply agreements to lock predictable pricing and prioritize capacity allocation. These strategic choices have knock-on effects: onshoring or regionalizing production can reduce exposure to import duties but may require significant capital expenditure and time to qualify new manufacturing sites under stringent regulatory frameworks. Moreover, increased import costs can influence pricing discussions with payers and government purchasers, intensifying pressure to demonstrate durable clinical benefit and cost-effectiveness.

Importantly, higher cross-border costs also elevate the value of supply chain transparency and inventory optimization, prompting firms to adopt more sophisticated forecasting, demand-sensing, and buffer stock policies. Regulatory and customs compliance teams will need to engage earlier in project planning to avoid unexpected classification changes that trigger tariffs. Overall, while tariffs are only one of many commercial variables, their cumulative impact can shape manufacturing strategies, partner selection, and the economics of bringing advanced Duchenne therapies to diverse markets.

Deriving practical commercial and clinical implications by integrating drug class, distribution channel, end-user context, form factors, and administration routes into segmentation-driven strategy

Segmentation analysis reveals distinct strategic implications when therapies are examined through multiple clinical and commercial lenses. When viewed by drug class, exon skipping agents, gene therapy approaches, and steroid regimens each demand unique clinical development paradigms and evidence packages; within gene therapy, the division between AAV-based and nonviral modalities affects vector selection, immunogenicity management, and manufacturing pathway decisions, while further consideration of AAV serotype choices such as serotype 6 and serotype 9 drives tissue targeting, dosing strategy, and production scale complexity. Examining distribution channels highlights the varying logistical and compliance requirements across hospital pharmacies, online pharmacies, and retail pharmacies, with each channel posing different cold-chain, reimbursement capture, and patient support needs. From an end-user perspective, the demands of home healthcare settings contrast sharply with hospital and specialty clinic environments, affecting training, monitoring cadence, and emergency preparedness for infusion-related events. Form and route of administration are central to adoption and patient adherence; capsules and oral tablets enable different patient journeys than injectables or intravenous administrations, and intramuscular, intravenous, and oral routes each carry specific clinical monitoring and administration infrastructure requirements.

Synthesizing these segmentation axes underscores that portfolio design cannot be siloed. For example, a gene replacement candidate using AAV9 intended for hospital-based intravenous administration will require different commercialization investments than an orally administered steroid therapy distributed through retail pharmacies for home use. Therefore, go-to-market planning must align clinical designs with downstream distribution, payer engagement, and patient-support services early in development. This integrated perspective enables tailored value propositions that reflect real-world use cases, reduce adoption friction, and support compelling evidence generation strategies for regulators and payers alike.

Evaluating regional regulatory, reimbursement, and operational nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform phased market entry and access strategies

Regional dynamics will shape the deployment and access pathways for Duchenne therapies, and each geography presents distinct regulatory, reimbursement, and operational considerations. In the Americas, there is a mature network of specialized centers, established rare disease clinical trial infrastructure, and payers that emphasize health technology assessment and value-based arrangements, which collectively influence the sequencing of approvals and commercial launches. In Europe, Middle East & Africa, regulatory pathways are diverse and reimbursement decision-making frequently involves national authorities with differing expectations for comparative effectiveness evidence, necessitating early alignment on heterogenous evidence strategies and localized health economic modeling. The Asia-Pacific region presents rapidly evolving clinical research capacity, a growing appetite for industry partnerships, and varied manufacturing ecosystems; however, market access strategies must account for divergent regulatory requirements, pricing controls, and patient access programs.

Consequently, regional strategies should prioritize flexible regulatory pathways, phased market entry plans, and partnerships that leverage local clinical expertise and distribution networks. Cross-border logistical planning is particularly important for advanced therapies with cold-chain or clinic-based administration needs, and regional manufacturing hubs can mitigate tariff or import vulnerabilities while supporting faster patient access. Ultimately, understanding these regional nuances enables more precise stakeholder engagement and increases the likelihood of early adoption by aligning product delivery models with local healthcare delivery architectures.

Analyzing how company strategies around vector engineering, manufacturing scale-up, and stakeholder engagement determine clinical progression and commercial readiness in Duchenne therapeutics

Company-level dynamics are pivotal in shaping the pace and direction of innovation in Duchenne therapeutics. Biotech firms focusing on exon skipping and small-molecule approaches continue to refine payload chemistry, delivery optimization, and patient-selection criteria to enhance clinical differentiation. Organizations pursuing gene replacement therapies are concentrating on vector engineering, serotype selection, and scalable GMP manufacturing to reduce batch-to-batch variability and support consistent clinical supply. Across the industry, strategic alliances-whether through research collaborations, licensing deals, or manufacturing partnerships-are frequently used to bridge capability gaps and accelerate time to clinic.

Investor and corporate priorities are also evolving: there is greater emphasis on operational execution, late-stage safety monitoring plans, and commercial readiness in parallel with clinical milestones. Companies with integrated strategies that align clinical development with manufacturing scale-up and payer engagement tend to navigate late-stage inflection points more effectively. In addition, patient advocacy groups and clinician networks are powerful conveners, influencing trial recruitment, endpoint selection, and post-approval evidence generation, so companies that invest in transparent stakeholder engagement and patient support infrastructure can strengthen both trial enrollment and long-term uptake. Finally, organizations that proactively address manufacturing capacity, supply chain resilience, and regulatory pathways are better positioned to translate R&D successes into accessible therapies for patients.

Adopt integrated actions linking early manufacturing planning, adaptive evidence generation, supply diversification, and patient-centered services to de-risk development and accelerate access

Industry leaders should adopt a coordinated, risk-balanced approach that links scientific strategy with manufacturing and market access planning to accelerate sustainable patient impact. Firstly, integrating manufacturing considerations into early clinical design decisions reduces the likelihood of late-stage supply constraints and enables clearer discussions with regulators about comparability and long-term follow-up. Secondly, firms should prioritize adaptive evidence generation that combines robust clinical endpoints with pragmatic real-world data collection to meet the needs of regulators and payers while supporting iterative product improvements. Thirdly, diversifying supplier networks and exploring regional manufacturing hubs can mitigate tariff and cross-border risks, while long-term capacity agreements with experienced biologics manufacturers can secure critical inputs.

Furthermore, investment in patient-centric services and digital monitoring platforms can improve adherence, capture meaningful outcomes, and strengthen value discussions with payers. Engaging patient advocacy groups early and transparently augments recruitment and aligns development programs with daily life improvements that matter to families. Lastly, leaders should pursue strategic partnerships-spanning research institutions, contract manufacturers, and specialty distribution channels-to fill capability gaps and accelerate time to broader access. Implementing these actions in concert will create a more resilient, evidence-driven approach to bringing transformative Duchenne therapies to patients.

Describe the mixed-methods analytical approach combining expert interviews, regulatory reviews, and supply chain mapping to validate strategic insights without relying on numerical market sizing

The research underpinning this executive synthesis utilized a mixed-methods approach to capture scientific, operational, and commercial dimensions relevant to Duchenne therapeutic development. Primary research included structured interviews with clinical experts, manufacturing specialists, payer advisors, and patient advocacy representatives to validate modality-specific challenges and evidence expectations. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trajectories, safety considerations, and trial endpoint evolution. Cross-validation steps compared insights from interviews with documentary evidence to ensure consistency and reduce bias.

Analytical methods emphasized qualitative triangulation and scenario-based risk assessment rather than quantitative market sizing. Special attention was given to supply chain mapping for biologics manufacturing and to evaluating the interplay between serotype selection and clinical strategy for gene therapies. Wherever applicable, regulatory precedent and published long-term follow-up frameworks informed the assessment of post-market evidence needs. Limitations include the evolving nature of clinical data and policy environments; consequently, readers are advised to consider these findings alongside emerging trial results and regulatory decisions as they become available.

Synthesize strategic priorities and execution imperatives that will determine whether scientific advances in Duchenne therapies translate into durable clinical benefit and broad patient access

In conclusion, the Duchenne therapeutic landscape is at a pivotal juncture where scientific innovation, manufacturing realities, and payer expectations converge to shape which therapies reach patients and how they are adopted in practice. Progress in exon skipping, gene therapy vectors, and optimized steroid regimens offers real potential to alter disease trajectories, but realizing that potential depends on synchronized planning across R&D, manufacturing, and commercial teams. Strategic investments in scalable manufacturing, early engagement with regulators and payers, comprehensive real-world evidence plans, and robust patient support models will be decisive in translating clinical promise into sustainable patient access.

As stakeholders navigate tariff policies, regional regulatory heterogeneity, and evolving evidence standards, flexibility and proactive stakeholder alignment will differentiate organizations that can rapidly convert scientific breakthroughs into durable clinical and commercial outcomes. The path forward requires integrated execution, transparent engagement with patient communities, and adaptive evidence strategies that prioritize measured benefit for patients while addressing the long-term sustainability of therapeutic access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Duchenne Muscular Dystrophy Drugs Market, by Drug Class

  • 8.1. Exon Skipping
  • 8.2. Gene Therapy
    • 8.2.1. Aav Based
      • 8.2.1.1. Serotype 6
      • 8.2.1.2. Serotype 9
    • 8.2.2. Nonviral
  • 8.3. Steroid Therapy

9. Duchenne Muscular Dystrophy Drugs Market, by Form

  • 9.1. Capsule
  • 9.2. Injectable
  • 9.3. Oral Tablet

10. Duchenne Muscular Dystrophy Drugs Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral

11. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Duchenne Muscular Dystrophy Drugs Market, by End User

  • 12.1. Home Healthcare Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Duchenne Muscular Dystrophy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Duchenne Muscular Dystrophy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Duchenne Muscular Dystrophy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Duchenne Muscular Dystrophy Drugs Market

17. China Duchenne Muscular Dystrophy Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anuh Pharma Limited
  • 18.6. Arlak Biotech Pvt.Ltd.
  • 18.7. Aurigene Pharmaceutical Services Ltd.
  • 18.8. Bayer Pharmaceutical
  • 18.9. Cipla Inc.
  • 18.10. Enomark
  • 18.11. Glasier Wellness, Inc.
  • 18.12. GlaxoSmithKline PLC
  • 18.13. Johnson & Johnson Services, Inc.
  • 18.14. Leo Pharma
  • 18.15. Lifecare Neuro Products Limited
  • 18.16. Mankind Pharma Ltd.
  • 18.17. Merck & Co., Inc.,
  • 18.18. MODASA Pharmaceuticals Pvt. Ltd.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. QndQ Derma
  • 18.22. RayBiotech, Inc.
  • 18.23. Ronyd Healthcare Pvt Ltd.
  • 18.24. Sarepta Therapeutics, Inc.
  • 18.25. Sumitomo Corporation
  • 18.26. Texas Pharmaceuticals Pvt. Ltd.
  • 18.27. Wellona Pharma
  • 18.28. Zuventus Healthcare Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 144. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 168. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 169. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 176. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)